The Division for Cancer Pharmacology (DCP) serves members with interests
in all aspects of basic and translational cancer pharmacology research.
Specific areas include, (but are not limited to) discovery and
preclinical development of new anticancer agents, preclinical toxicology
and adverse reactions to
anticancer drugs, technical developments in novel cancer-related target
and therapeutic identification, mechanisms of anticancer drug
resistance, mechanistic studies of novel therapeutic regimens,
pharmacogenetics of anticancer therapeutics, and biomarker studies in
anticancer drug response.